$INTT

INTEST CORP (INTT): Results of Operations and Financial Condition

INTEST CORP (INTT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 intt-20260731xpaexx991.htm EX-99.1 Document Exhibit 99.1 NEWS RELEASE 804 EAST GATE DRIVE, SUITE 200, MOUNT LAUREL, NJ 08054 FOR IMMEDIATE RELEASE InTest Reports Preliminary Second Quarter 2026 Results • Second Quarter Revenue Estimated to be Approximately $35 Million •

Original reporting
Published Jul 31, 2026, 12:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$INTT
Neutral
medium confidence
Mentioned
$INTT
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INTTNeutralMed
01

Why it matters

The company simultaneously (1) improves the top-line outlook, (2) lowers expected gross margin due to Alfamation-related issues, and (3) indicates an internal control material weakness will be reported, which can drive valuation and volatility around the upcoming Q2 results.

02

Market read

A guidance update with explicit margin revisions and an expected material weakness disclosure is a direct catalyst for earnings-quality and margin-trend positioning ahead of the Aug 10 Q2 print.

03

What to watch

Traders may underweight the earnings-quality angle: management expects to report a material weakness, even if they believe it is remediated, which can affect discount rates and buyer confidence in reported margins.

Relevance 7/10Novelty 8/10Timing: pre-market today, ahead of Aug 10 Q2 results call

Background

This is an SEC 8-K with a press release providing preliminary Q2 2026 estimates, a correction to previously reported Q1 gross margin, and updated FY26 guidance.

Company-level read

Ticker impact

$INTTNeutralMedium confidence
Context

InTest (INTT) raised FY26 revenue guidance to $135M-$140M but cut Q1 gross margin by 220 bps due to an Alfamation ERP-related accounting error.

Expected impact

Near-term volatility risk around the Aug 10 Q2 results call, with traders likely to focus on whether gross margin stabilization offsets the ERP/accounting-control concerns.

Evidence & confidence

The filing discloses concrete preliminary Q2 metrics, a specific Q1 gross profit overstatement ($750k), and an expected material weakness, all of which can re-rate near-term earnings quality and margin trajectory.

Market effects

Signals heightened margin and systems-integration risk for test and process technology suppliers with complex subsidiaries and project-based delivery.

Limited, primarily impacts US small/mid-cap industrial/test-equipment sentiment.

Low; demand strength is cited across end markets but no cross-border regulatory or macro shock is disclosed.

Counterpoint

The gross margin miss is partly explained by identifiable project mix and a discrete $2M shipping delay, so the raised revenue outlook could still translate into improving profitability in 2H if mix normalizes.

Key entities

  • InTest Corporation

    Supplier of test and process technology solutions; reports preliminary Q2 results, revises Q1 gross margin, and updates FY26 outlook.

  • Alfamation

    Operational entity where a new ERP system implementation contributed to overstated inventory and gross margin in Q1.

  • Duncan Gilmour

    CFO cited ERP implementation and Alfamation gross margin overstated as drivers of revisions.

  • Rich Rogoff

    CEO emphasized operational discipline and raised FY26 revenue outlook based on strengthening demand.

Related articles

$INTTMed

Why is inTest stock climbing today?

inTest Corp (INTT) shares rose 1.7% in pre-open trading after Northland upgraded the stock to “outperform” from “market perform” and set a $15.00 price target. Northland cited inTest’s preliminary Q2 2026 revenue estimate of about $35M and raised full-year 2026 revenue guidance to $135M-$140M, while noting a planned 220 bps gross margin reduction.

$HMNMed

Horace Mann Educators Q2 Earnings Call Highlights

Horace Mann (NYSE:HMN) reported Q2 call highlights. Management said auto frequency and severity trends were favorable and liability losses mid-single digits. It cut its full-year catastrophe-loss assumption to about $75M from $90M, while lowering total net investment income outlook to $465M-$475M. Revenue rose 8% YoY; life sales +20%.

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.